Compare ITRM & EQS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ITRM | EQS |
|---|---|---|
| Founded | 2015 | 1991 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.3M | 25.8M |
| IPO Year | 2018 | N/A |
| Metric | ITRM | EQS |
|---|---|---|
| Price | $0.47 | $1.80 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $9.00 | N/A |
| AVG Volume (30 Days) | ★ 1.3M | 5.2K |
| Earning Date | 11-14-2025 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $390,000.00 | ★ $1,377,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $325.95 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 21.11 |
| 52 Week Low | $0.36 | $0.74 |
| 52 Week High | $3.02 | $2.49 |
| Indicator | ITRM | EQS |
|---|---|---|
| Relative Strength Index (RSI) | 45.29 | 45.22 |
| Support Level | $0.40 | $1.77 |
| Resistance Level | $0.50 | $1.90 |
| Average True Range (ATR) | 0.06 | 0.11 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 58.91 | 31.43 |
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
Equus Total Return Inc is a United States-based closed-end management investment company. It invests mainly in companies pursuing growth either through acquisition or organically, leveraged buyouts, management buyouts, and recapitalizations of existing businesses or special situations, and achieves capital appreciation by making investments in equity and equity-oriented securities issued by privately-owned companies or smaller public companies in transactions.